BWX Technologies enters the second week of June with an unusual options skew — one that stands out sharply against an otherwise calm short-selling picture.
The clearest anomaly this week is in the options market. The put/call ratio jumped to 0.56 on June 9, nearly four standard deviations above its 20-day average of 0.31. That's close to the highest reading of the past year, with only the April 30 reading of 0.57 coming in higher. For a stock that has spent weeks running a consistently call-heavy options book, the single-session shift toward puts is the kind of divergence worth flagging.
The lending market tells a completely different story. Short interest has been steadily unwinding — down 7.3% on the week and 18.7% over the past month, now sitting at 2.8% of the free float. Availability is extremely loose at more than 2,200%, meaning there are roughly 22 shares available to borrow for every one currently lent out. That compares to a 52-week low availability reading of about 770% — itself still generous — so the borrow market has never been meaningfully tight on this name. Cost to borrow ticked up about 10% on the week to 0.50%, but in absolute terms that remains trivially low. The short score has drifted down to 33.9 from 35.2 two weeks ago, consistent with bears quietly reducing exposure rather than pressing new positions. Positioning here is very clearly not crowded on the short side.
The Street, however, is broadly constructive. Eight analysts carry buy ratings, with a consensus mean target of $238 — roughly 26% above the current price of $188.96. The most notable recent move came on May 15, when Deutsche Bank's Scott Deuschle upgraded BWXT to Buy from Hold and lifted his target from $205 to $255, citing what appears to be growing conviction in the nuclear defense and SMR cycle. Truist raised its target around the same time but held at Hold. The bull case centres on BWXT's monopoly position as sole supplier of nuclear propulsion systems to the U.S. Navy, a predictable government revenue stream, and growing commercial momentum tied to small modular reactor programmes. The bear case points to regulatory risk in the medical isotope division — specifically the Tc-99 programme and Ac-225 trials — and the longer lead times on SMR adoption versus current valuations. On valuation, the stock trades at around 38x trailing earnings and 27x EV/EBITDA, with both multiples drifting down about 4-5 points over the past 30 days in line with the stock's 8% monthly decline. The EV/EBIT factor score ranks in the bottom decile of the universe, confirming the premium the market is paying for BWXT's defensive growth profile.
Insider activity introduces a note of caution. CEO Rex Geveden sold just over 10,000 shares on May 12 across multiple tranches — roughly $2 million at prices between $204 and $207. CFO Mike Fitzgerald added two sell transactions on May 6 and May 11, totalling around $854,000 at prices above $209. Neither sale is catastrophically large relative to their respective holdings, and both came at prices meaningfully above today's $188.96, which partly explains the stock's drift since. Net insider activity over the 90-day window is technically positive at around $9.6 million — but that reflects award transactions inflating the gross figure rather than open-market buying.
Among correlated peers, AIR led the group with a near 9% weekly gain. CW added 1.7%, roughly in line with BWXT's 0.9% week. KTOS was the notable laggard, off more than 11% on the week. BWXT's modest weekly advance sits near the middle of the peer range, offering no particular read-through either way.
The next scheduled earnings release is August 4. The single-session options shift on June 9 is worth watching to see whether it represents an isolated hedge or the beginning of a more sustained rotation toward downside protection ahead of that print.
See the live data behind this article on ORTEX.
Open BWXT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
